Integrated seroprevalence-based assessment of Wuchereria bancrofti and Onchocerca volvulus in two lymphatic filariasis evaluation units of Mali with the SD Bioline Onchocerciasis/LF IgG4 Rapid Test.
Animals
Antibodies, Helminth
/ blood
Child
Cross-Sectional Studies
Elephantiasis, Filarial
/ blood
Humans
Immunoglobulin G
/ blood
Immunologic Tests
Mali
/ epidemiology
Neglected Diseases
/ blood
Onchocerca volvulus
/ immunology
Onchocerciasis
/ blood
Seroepidemiologic Studies
Wuchereria bancrofti
/ immunology
Journal
PLoS neglected tropical diseases
ISSN: 1935-2735
Titre abrégé: PLoS Negl Trop Dis
Pays: United States
ID NLM: 101291488
Informations de publication
Date de publication:
01 2019
01 2019
Historique:
received:
27
09
2018
accepted:
08
12
2018
revised:
11
02
2019
pubmed:
31
1
2019
medline:
24
4
2019
entrez:
31
1
2019
Statut:
epublish
Résumé
Mali has become increasingly interested in the evaluation of transmission of both Wuchereria bancrofti and Onchocerca volvulus as prevalences of both infections move toward their respective elimination targets. The SD Bioline Onchocerciasis/LF IgG4 Rapid Test was used in 2 evaluation units (EU) to assess its performance as an integrated surveillance tool for elimination of lymphatic filariasis (LF) and onchocerciasis. A cross sectional survey with SD Bioline Onchocerciasis/LF IgG4 Rapid Test was piggy-backed onto a transmission assessment survey (TAS) (using the immunochromatographic card test (ICT) Binax Filariasis Now test for filarial adult circulating antigen (CFA) detection) for LF in Mali among 6-7 year old children in 2016 as part of the TAS in two EUs namely Kadiolo-Kolondieba in the region of Sikasso and Bafoulabe -Kita-Oussoubidiagna-Yelimane in the region of Kayes. In the EU of Kadiolo- Kolondieba, of the 1,625 children tested, the overall prevalence of W. bancrofti CFA was 0.62% (10/1,625) [CI = 0.31-1.09]; while that of IgG4 to Wb123 was 0.19% (3/1,600) [CI = 0.04-0.50]. The number of positives tested with the two tests were statistically comparable (p = 0.09). In the EU of Bafoulabe-Kita-Oussoubidiagna-Yelimane, an overall prevalence of W. bancrofti CFA was 0% (0/1,700) and that of Wb123 IgG4 antibody was 0.06% (1/1,700), with no statistically significant difference between the two rates (p = 0.99). In the EU of Kadiolo- Kolondieba, the prevalence of Ov16-specific IgG4 was 0.19% (3/1,600) [CI = 0.04-0.50]. All 3 positives were in the previously O. volvulus-hyperendemic district of Kolondieba. In the EU of Bafoulabe-Kita-Oussoubidiagna-Yelimane, an overall prevalence of Ov16-specific IgG4 was 0.18% (3/1,700) [CI = 0.04-0.47]. These 3 Ov16 IgG4 positives were from previously O.volvulus-mesoendemic district of Kita. The SD Bioline Onchocerciasis/LF IgG4 Rapid test appears to be a good tool for integrated exposure measures of LF and onchocerciasis in co-endemic areas.
Sections du résumé
BACKGROUND
Mali has become increasingly interested in the evaluation of transmission of both Wuchereria bancrofti and Onchocerca volvulus as prevalences of both infections move toward their respective elimination targets. The SD Bioline Onchocerciasis/LF IgG4 Rapid Test was used in 2 evaluation units (EU) to assess its performance as an integrated surveillance tool for elimination of lymphatic filariasis (LF) and onchocerciasis.
METHODOLOGY/PRINCIPAL FINDINGS
A cross sectional survey with SD Bioline Onchocerciasis/LF IgG4 Rapid Test was piggy-backed onto a transmission assessment survey (TAS) (using the immunochromatographic card test (ICT) Binax Filariasis Now test for filarial adult circulating antigen (CFA) detection) for LF in Mali among 6-7 year old children in 2016 as part of the TAS in two EUs namely Kadiolo-Kolondieba in the region of Sikasso and Bafoulabe -Kita-Oussoubidiagna-Yelimane in the region of Kayes. In the EU of Kadiolo- Kolondieba, of the 1,625 children tested, the overall prevalence of W. bancrofti CFA was 0.62% (10/1,625) [CI = 0.31-1.09]; while that of IgG4 to Wb123 was 0.19% (3/1,600) [CI = 0.04-0.50]. The number of positives tested with the two tests were statistically comparable (p = 0.09). In the EU of Bafoulabe-Kita-Oussoubidiagna-Yelimane, an overall prevalence of W. bancrofti CFA was 0% (0/1,700) and that of Wb123 IgG4 antibody was 0.06% (1/1,700), with no statistically significant difference between the two rates (p = 0.99). In the EU of Kadiolo- Kolondieba, the prevalence of Ov16-specific IgG4 was 0.19% (3/1,600) [CI = 0.04-0.50]. All 3 positives were in the previously O. volvulus-hyperendemic district of Kolondieba. In the EU of Bafoulabe-Kita-Oussoubidiagna-Yelimane, an overall prevalence of Ov16-specific IgG4 was 0.18% (3/1,700) [CI = 0.04-0.47]. These 3 Ov16 IgG4 positives were from previously O.volvulus-mesoendemic district of Kita.
CONCLUSIONS/SIGNIFICANCE
The SD Bioline Onchocerciasis/LF IgG4 Rapid test appears to be a good tool for integrated exposure measures of LF and onchocerciasis in co-endemic areas.
Identifiants
pubmed: 30699120
doi: 10.1371/journal.pntd.0007064
pii: PNTD-D-18-01466
pmc: PMC6370230
doi:
Substances chimiques
Antibodies, Helminth
0
Immunoglobulin G
0
Types de publication
Evaluation Study
Journal Article
Research Support, N.I.H., Intramural
Research Support, U.S. Gov't, Non-P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0007064Subventions
Organisme : Intramural NIH HHS
ID : Z01 AI001063
Pays : United States
Organisme : NIAID NIH HHS
ID : Z01 AI001063
Pays : United States
Déclaration de conflit d'intérêts
I have read the journal's policy and the authors of this manuscript have the following competing interests: Thomas B. Nutman is among the patent holders for Wb123 and Ov16 (no longer under patent) and, through the National Institutes of Health, has received licensing/royalty fees for Wb123.
Références
Ann Trop Med Parasitol. 2002 Mar;96 Suppl 1:S29-39
pubmed: 12081248
J Infect Dis. 2006 Jul 15;194(2):216-21
pubmed: 16779728
Mali Med. 2006;21(1):12-7
pubmed: 17390523
Ann Trop Med Parasitol. 2008 Sep;102 Suppl 1:13-7
pubmed: 18718148
PLoS Negl Trop Dis. 2009 Jul 21;3(7):e497
pubmed: 19621091
Am J Trop Med Hyg. 2010 Jul;83(1):21-7
pubmed: 20595472
PLoS Negl Trop Dis. 2012;6(3):e1574
pubmed: 22448294
PLoS Negl Trop Dis. 2012;6(9):e1825
pubmed: 23029586
PLoS Negl Trop Dis. 2012;6(12):e1941
pubmed: 23236534
Am J Trop Med Hyg. 2013 Jul;89(1):11-5
pubmed: 23690552
Bull Soc Pathol Exot. 2015 Aug;108(3):181-7
pubmed: 25476256
Clin Vaccine Immunol. 2015 Aug;22(8):896-901
pubmed: 26018537
Parasit Vectors. 2016 Jun 13;9(1):338
pubmed: 27296630
Am J Trop Med Hyg. 2016 Dec 7;95(6):1417-1423
pubmed: 27729568
Parasit Vectors. 2016 Dec 3;9(1):628
pubmed: 27912789
PLoS Negl Trop Dis. 2017 Jan 23;11(1):e0005314
pubmed: 28114304
Epidemics. 2017 Mar;18:4-15
pubmed: 28279455
N Engl J Med. 2017 Nov 23;377(21):2044-2052
pubmed: 29116890
Am J Trop Med Hyg. 2018 Jan;98(1):15-20
pubmed: 29165213
Int Health. 2018 Mar 1;10(suppl_1):i14-i19
pubmed: 29471341
PLoS Negl Trop Dis. 2018 Mar 15;12(3):e0006249
pubmed: 29543797
Bull World Health Organ. 1979;57(4):655-62
pubmed: 316743